July 7, 2021 — Flywheel, a leading cloud-scale informatics platform for medical research and collaboration, and HealthMyne, a pioneer in applied radiomics, announced today a partnership that will combine the companies’ technologies to accelerate radiomics research and advance clinical trials outcomes for life sciences and clinical research clients.
Combining Flywheel’s comprehensive informatics platform with HealthMyne’s artificial-intelligence-enabled radiomics solutions provides an innovative approach for clinical trials and oncology research. The combined platform features an open, extensible architecture to facilitate the automation and streamlining of data curation, quantitative image analysis and radiomic computation.
Flywheel provides an end-to-end research workflow solution that helps life sciences, clinical and academic researchers transform productivity, curation, and collaboration with medical research data. HealthMyne’s solution performs radiomic analysis, which is the process of extracting and converting quantitative descriptors of tumor structure and lesion characteristics into mineable data, to support emerging therapy development and response assessment approaches.
Together, the combined technologies will enable life sciences companies and researchers to gain a deeper understanding of tumor or lesion response to a specific therapy, acquire new insights to enrich clinical trials and leverage novel data to better personalize treatments for the best patient outcomes.
“By combining medical imaging and genomics data on a single cloud-scalable platform, researchers can now enter uncharted territory in healthcare innovation - streamlined, enterprise-scale radiomics research. HealthMyne's innovative algorithms on Flywheel's platform will not only provide valuable insights in clinical trials but also accelerate the development of new discoveries in cancer research," said Jim Olson, CEO, Flywheel.
“Leveraging Flywheel’s bioinformatics platform coupled with HealthMyne’s ability to compute advanced imaging analytics and reveal radiomic insights further enhances the understanding of disease progression, treatment response and clinical trial outcomes,” said Rose Higgins, CEO, HealthMyne. “This partnership will enable our clients to fully realize the value of their imaging pipeline to help tackle complex diseases such as cancer.”
For more information: www.healthmyne.com
October 24, 2025 
